This Medudy course is a video tutorial for physicians on the topic of “Biliary carcinomas: First-line chemoimmunotherapy and marker-based treatment sequences.”
Prof. Dr. Dirk Arnold, Director of the Asklepios Tumor Center Hamburg and the Department of Oncology, Hematology, Palliative Medicine, Rheumatology, and Pulmonology at the Asklepios Clinic Altona, provides an overview in this video of current systemic therapy for advanced biliary carcinoma—with a focus on guideline-based first-line therapy, Phase III data on the combination of gemcitabine, cisplatin, and immune checkpoint inhibitors, as well as the early integration of molecular pathological diagnostics into treatment sequencing.
The paper outlines the historical development from the ABC-02 study to the current standard of care for chemoimmunotherapy—using durvalumab or pembrolizumab in combination with gemcitabine and cisplatin—and discusses the underlying evidence from the Phase IIIstudies TOPAZ-1 and KEYNOTE-966, including differences in study design, as well as the guideline-based equivalence of both regimens according to S3 and ESMO recommendations.
The second part discusses the importance of early molecular pathological characterization—particularly in intrahepatic cholangiocarcinoma—with a focus on clinically relevant alterations such as IDH1 mutations, FGFR2 fusions, BRAF V600E, MSI-H/dMMR, HER2, and NTRK fusions. Finally, biomarker-informed options in the second-line setting, as well as the role of FOLFOX and clinical trials, are discussed in a practical context for the subsequent treatment sequence.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
This course was made possible with the generous support of MSD.
By the end of this course, you will know:
- Current guideline-based first-line therapy for advanced biliary carcinoma
- the key data from TOPAZ-1 and KEYNOTE-966
- the importance of early molecular pathological diagnosis
- biomarker-guided options in second-line and subsequent treatment sequences
